Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.
You may also be interested in...
Pfizer and Lilly said tanezumab reduced pain in a Phase III osteoarthritis study, but safety is the biggest question for NGF inhibitors. Yet, while Regeneron and Teva discontinued dosing for their fasinumab at its highest dose, tanezumab was effective at both doses in its first Phase III test.
Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.
Reeducating prescribers on treating pain will take a long time, FDA Commissioner Scott Gottlieb tells Senate HELP Committee Members.